Antiviral drug profile of human influenza A & B viruses circulating in india: 2004-2011

Indian Journal of Medical Research

Volumn 140, Issue AUG 2014, 2014, Pages 244-251

  Potdar, V A ^a   Dakhave, M R ^a   Kulkarni, P B ^a   Tikhe, S A ^a   Broor, S ^b   Gunashekaran, P ^c   Chawla Sarkar, M ^d   Abraham, A ^e   Bishwas, D ^f   Patil, K N ^a   Kadam, A A ^a   Kode, S S ^a   Mishra, A C ^a   Chadha, S ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Institute of Preventive Medicine   (India)

^d NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^e CHRISTIAN MEDICAL COLLEGE   (India)

^f REGIONAL MEDICAL RESEARCH CENTRE   (India)

Author keywords

Amantadine; Drug resistance; India; Influenza; Oseltamivir; Real time reverse transcription

Indexed keywords

ADAMANTANE; ASPARAGINE; LEUCINE; OSELTAMIVIR; PHENYLALANINE; SERINE; SIALIDASE; AMANTADINE; GENETIC MARKER;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ENZYME INHIBITION ASSAY; FLUORESCENT NEURAMINIDASE INHIBITION ASSAY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IC50; INDIA; INFECTION CONTROL; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS; NONHUMAN; PHENOTYPE; PHYLOGENY; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS ISOLATION; BIOLOGICAL MODEL; CLUSTER ANALYSIS; DNA SEQUENCE; GENETIC MARKER; GENETICS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MISSENSE MUTATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION;

AMANTADINE; BASE SEQUENCE; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; GENETIC MARKERS; HUMANS; INDIA; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; OSELTAMIVIR; PHYLOGENY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 84907486046     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Dolin, R. Antiviral chemotherapy and chemoprophylaxis. Science 1985; 227: 1296-303.
2. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6.
3. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of the resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18 (Suppl B): 19-29.
4. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, et al. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 249-57.
5. Bright RA, Medina MJ, Xu X, Wallis TR, Davis XM, Povinelli L, et al. Incidence of adamantine resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81.
6. Barr IG, Deng YM, Iannello P, Hurt AC, Komadina N. Adamantane resistance in influenza A(H1) viruses increased in 2007 in South East Asia but decreased in Australia and some other countries. Antiviral Res 2008; 80: 200-5.
7. Cheng PKC, Leung TWC, Ho ECM, Leung PCK, Ng AYY, Lai MYY, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerging Infect Dis 2009; 15: 966-8.
8. Hay AJ, Collins PJ, Russell J. Antivirals and resistance. Monogr Virol 2008; 27: 251-70.
9. Hauge S, Dudman S, Borgen K, Lackenby A, Hungnes A. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerging Infect Dis 2009; 15: 155-62.
10. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13 (S): 1-2 pii.
11. Jong De M, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353: 2667-72.
12. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW, Barr IG, et al. Neuraminidase inhibitor-resistant and sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006; 50: 1872-4.
13. Sheu TG, Deyde VM, Adhiambo MO, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-92.
14. Sleeman K, Sheu TG, Moore Z, Kilpatrick S, Garg S, Fry AM, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerging Infect Dis 2011; 17: 2043-6.
15. Kimura K, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297: 1435-42.
16. Ison, MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193: 760-4.
17. Drug Susceptibility of Swine-Origin Influenza A (H1N1) Viruses, April 2009. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2009; 58: 433-5.
18. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365: 2541-2.
19. Storms AD, Gubareva LV, Su S, Wheeling JT, Adhiambo M.O., Pan C.Y., et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerging Infect Dis 2012; 18: 308-11.
20. Chadha MS, Broor S, Gunasekaran P, Potdar VA, Krishnan A, Chawla-Sarkar M, et al. Multi site virological influenza surveillance in India: 2004-2008. Influenza Other Respir Viruses 2011; 6: 196-203.
21. World Health Organization, WHOManual in Animal Influenza Diagnosis and Surveillance 2001. Available from: http://www.wpro.who.int/NR/rdonlyres/EFD2B9A7-22654AD0-BC98-97937B4FA83C/0/manualon animal aidiagnosisandsurveillance.pdf., Accessed on July 12, 2012.
22. Hurt AC, Barr IG, Hartel G, Hampson AW. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62: 37-45.
23. Alvarez AC, Brunck ME, Boyd V, Lai R., Virtue E., Chen W, et al. A broad spectrum, one-step reverse-transcription PCRamplification of the neuraminidase gene from multiple subtypes of influenza A virus. Virol J 2008; 5: 77
24. Pachucki CT, Khurshid MA, Nawrock J. Utility of reverse transcriptase PCR for rapid diagnosis of Influenza A virus infection and detection of amantadine resistant influenza A virus Isolates. J Clin Microbiol 2004; 42: 2796-8.
25. Sheu TG, Deyde VM, Garten R.J., Klimov A.I., Gubareva LV. Detection of antiviral resistance and genetic lineage markers influenza B virus neuraminidase using pyrosequencing. Antiviral Res 2010; 85: 354-60.
26. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses due to substitution of aspartic acid 151 in the catalytic site - Role in virus attachment? J Virol 2010; 84: 6769-81.
27. Tamura K, Dudley J, Nei M, Kumar S. Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-9.
28. Monitoring drug resistance in influenza viruses Report of the Regional Workshop Nonthaburi, Thailand 23-28 August 2010. Available from: http://www.searo.who.int/LinkFiles/BCT_Reports_HLM-409.pdf, Accessed on August 31, 2010.
29. Nelson M I, Simonsen L, Viboud C, Miller MA, Holmes EC. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 2009; 388: 270-8.
30. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, et al. Neuraminidase Inhibitor Susceptibility Network; Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antiviral Ther 2009; 14: 751-61.
31. Bloom J, Gong L, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328: 1272-5.